medigraphic.com
ISSN 1817-5996 (Electronic)

2021, Number 1

<< Back Next >>

Rev Cub de Reu 2021; 23 (1)

FRAX as a tool to assess the risk of fractures in the general population and special risk groups

Reyes LGA, Guibert TZM, Reyes GG, Martínez QJ, Molinet FE, Carrillo LD, Frías PR

Language: Spanish
References: 59
Page: 1-23
PDF size: 527.63 Kb.


ABSTRACT

The FRAX is a tool that has a computerized algorithm developed by the World Health Organization, based on global models of population cohorts, combined with clinical risk factors, which measures the risk of fracture. The tool was initially designed for use by primary care physicians in postmenopausal women and men over 50 years of age, although it is generally valid between 40-90 years. We set out to develop a clinical epidemiological study on osteoporosis and fractures in the general population and some special risk groups that include post-menopausal women, patients with rheumatic, endocrine, cancer and HIV-infected conditions, as well as the role played by FRAX as a measurement tool. The ten-year risk of fracture related to the importance of knowing and identifying the main vulnerable or risk groups for osteoporosis and fractures in the Cuban population constitutes a great challenge. This application is a priority for those groups previously identified as it will allow us to know the short and long-term risks of fractures and implement the correct use of DXA studies, available in the country with a rational use and therapeutic decision-making.


REFERENCES

  1. Kanis JA, Harvey NC, Johansson H, Odén A, Leslie WD, McCloskey EV. FRAX and fracture prediction without bone mineral density. Climacteric. 2015 [Acceso 12/09/2020];18(Sup2):2-9. Disponible en: https://www.tandfonline.com/doi/abs/10.3109/13697137.2015.1092342

  2. Chao AS, Chen FP, Lin YC, Huang TS, Fan CM, Yu YW. Application of the World Health Organization Fracture Risk Assessment Tool to predict need for dual-energy X-ray absorptiometry scanning in postmenopausal women. Taiwan J Obstet Gynecol. 2015 Dec [Acceso 12/09/2020];54(6):722-5. Disponible en: https://www.sciencedirect.com/science/article/pii/S1028455915002363

  3. Masud T, Binkley N, Boonen S, Hannan MT, Members FPDC. Official Positions for FRAX(R) clinical regarding falls and frailty: can falls and frailty be used in FRAX(R)? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R). J Clinical Densitometry. 2011 [Acceso 12/09/2020];14(3):194-204. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1094695011001223

  4. European AIDS Clinical Society (EACS). Guidelines. Version 8, October 2015. [Acceso 12/09/2020]. Disponible en: http://www.eacsociety.org/files/2-english_rev-20151221.pdf

  5. Reyes LLerena GA, Guibert Toledano M, Millán Marcelo JC. Manifestaciones reumáticas en la epidemia VIH-SIDA en la era previa a la terapia antirretroviral sumamente activa en Cuba. Una puesta al día. Rev Peruana Reumatología. 2016;(22):25-33.

  6. Reyes Llerena GA, Guibert Toledano M, Penedo Coello A, Pérez Rodríguez A, Baez Dueñas RM, Charnicharo Vidal R. Community study based to estimate the prevalence and burden of illness of rheumatic diseases in Cuba. A COPCORD study. J Clin Rheumatol. 2009 [Acceso 12/09/2020];15(2):51-5. Disponible en: https://pubmed.ncbi.nlm.nih.gov/19265344/

  7. Kanis JA, Odén A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007 [Acceso 12/09/2020];18(8):1033·46. Disponible en: https://link.springer.com/article/10.1007/s00198-007-0343-y

  8. Yin MT, Skanderson M, Shiau S. Fracture prediction with modified FRAX in older HIV+ and HIV·men. Conference of Retroviruses and Opportunistic Infections. Seattle: CROI; 2015. [Acceso 12/09/2020]. Disponible en: https://www.croiconference.org/abstract/fracture-prediction-modified-frax-older-hiv-and-hiv-men/

  9. Oka R, Ohira M, Suzuki S, Yoshida T, Koide H, Tanaka T, et al. Fracture risk assessment tool (FRAX) and for the diagnosis of osteoporosis in Japanese middle-aged and elderly women: Chiba bone survey. Endocr J. 2018 [Acceso 12/09/2020];65(2):193-202. Disponible en: https://www.jstage.jst.go.jp/article/endocrj/65/2/65_EJ17-0331/_article/-char/ja/

  10. Kanis JA, Johnell O, Odén A, Johansson H, McCloskey E. FRAXTM and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008 [Acceso 12/09/2020];19:385-97. Disponible en: https://link.springer.com/article/10.1007/s00198-007-0543-5

  11. Fujiwara S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukunaga M. Fracture prediction from bone mineral density in Japanese men and women. J Bone and Mineral Research. 2003;18(8):1547-53.

  12. Lundgren JD, Battegay M, Behrens G, De Wit S, Guaraldi G, Katlama C, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 2008 [Acceso 12/09/2020];9(2):72-81.

  13. Kim BY, Kim HA, Jung JY, Choi ST, Kim JM, Kim SH, et al. Impact of the Fracture Risk Assessment Tool on the Treatment Decision for Osteoporosis in Patients with Knee Osteoarthritis: A Multicenter Comparative Study of the Fracture Risk Assessment Tool and World Health Organization Criteria. J Clin Med. 2019 [Acceso 12/09/2020];8(7):E918. Disponible en: https://www.mdpi.com/2077-0383/8/7/918

  14. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis international. 2013 [Acceso 12/09/2020];24(1):23-57. Disponible en: https://link.springer.com/article/10.1007/s00198-012-2074-y

  15. Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK; 2008. [Acceso 12/09/2020]. Disponible en: https://www.sheffield.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf

  16. Neuprez A, Johansson H, Kanis JA, McCloskey EV, Odén A, Bruyère O, et al. Rationalisation du remboursement des médicaments de l’ostéoporose: de la mesure isolée de la densité osseuse a l’intégration des facteurs cliniques de risque fractura ire. Validation de l’algorithme FRAX. Rev Med Liege. 2009 [Acceso 12/09/2020];64(12):612-9. Disponible en: https://orbi.uliege.be/bitstream/2268/80892/1/Rationalisation%20du%20Remboursement%20des%20m%c3%a9dicaments%20de%20l%27ost%c3%a9oporose...pdf

  17. Bastos-Silva Y, Aguiar LB, Pinto-Neto AM, Baccaro LF, Costa-Paiva L. Correlation between osteoporotic fracture risk in Brazilian postmenopausal women calculated using the FRAX with and without the inclusion of bone densitometry data. Arch Osteoporos. 2016 [Acceso 12/09/2020];11(1):16. Disponible en: https://link.springer.com/article/10.1007/s11657-015-0255-y

  18. Sociedad Cubana de Endocrinología, Sociedad Cubana de Reumatología. Guías nacionales para el diagnóstico y tratamiento de la Osteoporosis. Soc Cubana de Endocrinología, Soc Cubana de Reumatología. Rev Cubana Endocrinol. 2014 [Acceso 12/06/2018];25(1):1-34. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532014000100001

  19. Haugeberg G, Ørstavik RE, Kvien TK. Effects of rheumatoid arthritis on bone. Curr Opin Rheumatol. 2003 [Acceso 12/09/2020];15(4):469-75. Disponible en: https://journals.lww.com/co-rheumatology/Fulltext/2003/07000/Effects_of_rheumatoid_arthritis_on_bone.16.aspx?casa_token=FVeEt

  20. Rossini M, Viapiana O, Adami S, Fracassi E, Idolazzi L, Dartizio C, et al. In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clin Exp Rheumatol. 2015 [Acceso 10/10/2020];33(1):77-83. Disponible en: https://www.clinexprheumatol.org/article.asp?a=7389

  21. Rossini M, Bagnato G, Frediani B, Iagnocco A, La montagna G, Minisola G, et al. Relationship of focal erosions, bone mineral density, and parathyroid hormone in rheumatoid arthritis. J Rheumatol. 2011 [Acceso 12/09/2020];38(6):997-1002. Disponible en: https://www.jrheum.org/content/38/6/997.short

  22. Phuan-udo R, Lektrakul M, Katchamart W. The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis. Clinical Rheumatology. 2018 [Acceso 10/10/2020];37(10):2603-10. Disponible en: https://link.springer.com/article/10.1007/s10067-018-4218-8

  23. Raterman HG, Lems WF. Pharmacological management of osteoporosis in rheumatoid arthritis patients: a review of the literature and practical guide. Drugs & Aging. 2019 [Acceso 12/09/2020];36(2):1061-72. Disponible en: https://link.springer.com/article/10.1007/s40266-019-00714-4

  24. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010 [Acceso 12/09/2020];62(11):1515-26. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/acr.20295

  25. Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid Therapy: a cross-sectional outpatient study. Bone. 2006 [Acceso 12/09/2020];39(2):253-9. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S8756328206002626

  26. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011 [Acceso 12/09/2020];22(9):2395. Disponible en: https://link.springer.com/article/10.1007/s00198-011-1713-z

  27. Ye B, Huang YH, Zhang L, Tian XL, Zhang Q, Lu MH, et al. Clinical analysis of FRAX in the assessment of fracture risk in patients with rheumatic disease in three medical center. Zhonghua Yi Xue Za Zhi. 2019 [Acceso 10/10/2020];99(42):3345-9. Disponible en: https://europepmc.org/article/med/31715673

  28. Siris ES, Baim S, Nattiv A. Primary care use of FRAX®: absolute fracture risk assessment in postmenopausal women and older men. Postgrad Med. 2010 Jan [Acceso 10/10/2020];122(1):82-90. Disponible en: https://europepmc.org/article/med/31715673

  29. Kanis JA, Cooper C, Rizzoli R, Reginster JY. Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcified tissue international. 2019;104(3):235-8.

  30. Blake GM, Fogelman I. An update on dual-energy x-ray absorptiometry. In Seminars in nuclear medicine. 2010;40(1):62-73.

  31. Briot K, Cortet B, Thomas T, Audran M, Blain H, Breuil V, et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine. 2012 [Acceso 12/09/2020];79(3):304-13. Disponible en: https://www.sciencedirect.com/science/article/pii/S1297319X1200053X

  32. Nogués X, Nolla JM, Casado E, Jódar E, Muñoz-Torres M, Quesada-Gómez JM, et al. Spanish consensus on treat to target for osteoporosis. Osteoporosis Int. 2018 [Acceso 12/09/2020];29:489-99. Disponible en: https://link.springer.com/article/10.1007/s00198-017-4310-y

  33. Bodmer NS, Häuselmann HJ, Frey D, Aeberli D, Bachmann LM. Expert consensus on relevant risk predictors for the occurrence of osteoporotic fractures in specific clinical subgroups – Delphi survey. BMC Rheumatology. 2019 [Acceso 12/09/2020];3(50). Disponible en: https://bmcrheumatol.biomedcentral.com/articles/10.1186/s41927-019-0099-y

  34. Chen JF, Yu SF, Hsu CY, Chiu WC, Wu CH, Lai HM, et al. The role of bone mineral density in therapeutic decision-making using the Fracture Risk Assessment Tool (FRAX): a sub-study of the Taiwan Osteoporosis Survey (TOPS). Arch Osteoporos. 2019 [Acceso 10/10/2020];14(1):101. Disponible en: https://link.springer.com/article/10.1007/s11657-019-0653-7

  35. Schacter GI, Leslie WD. Based Measurements in Diabetes: Can They Predict Fracture Risk? Calcif Tissue Int. 2017 [Acceso 10/10/2020];100(2):150-64. Disponible en: https://link.springer.com/article/10.1007%2Fs00223-016-0191-x

  36. Bonaccorsi G, Messina C, Cervellati C, Maietti E, Medini M, Rossini M, et al. Fracture risk assessment in postmenopausal women with diabetes: comparison between De FRA and FRAX tools. Gynecol Endocrinol. 2018 [Acceso 10/10/2020];34(5):404-8. Disponible en: https://www.tandfonline.com/doi/abs/10.1080/09513590.2017.1407308

  37. Sessa A, Esposito A, Iavicoli GD, Lettieri E, Dente G, Costa C, et al. Immunosuppressive agents and bone disease in renal transplant patients with hypercalcemia. Trasplant Proc. 2010 [Acceso 12/09/2020];42(4):1148-55. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S004113451000357X

  38. Ban TH, Kim JH, Jang HB, Lee YS, Choi BS, Park CW, et al. Clinical effects of pre-transplant serum 25-hydroxyvitamin D level on post-transplant immunologic and non-immunologic outcomes in kidney transplant recipients. Trasplant Inmunol. 2017 [Acceso 12/09/2020];40:51-6. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0966327416301599

  39. Kalantar-Zadeh K, Molnar MZ, Kovesdy CP, Mucsi I, Bunnapradist S. Management of mineral and bone disorder after kidney transplantation. Curr Opin Nephrol Hypertensi. 2012 [Acceso 12/09/2020];21(4):389-403. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532932/

  40. Wang J, Yao M, Xu JH, Shu B, Wang YJ, Cui XJ. Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials. Osteop Int. 2016 [Acceso 12/09/2020];27(5):1683-90. Disponible en: https://link.springer.com/article/10.1007%2Fs00198-015-3465-7

  41. Pundole X, Murphy WA, Ebede CC, Karim E, Manocha S, Don-Pedro D, et al. Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation. Arch Osteoporos. 2018 [Acceso 12/09/2020];13(1):38. Disponible en: https://link.springer.com/article/10.1007/s11657-018-0453-5

  42. Wang J, Wang X, Fang Z, Lu N, Han L. Effect of FRAX on the Prediction of Osteoporotic Fractures in Urban Middle-aged and Elderly Healthy Chinese Adults. Clinics (Sao Paulo). 2017 [Acceso 12/09/2020];72(5):289-93. Disponible en: https://www.scielo.br/scielo.php?pid=S1807-59322017000500289&script=sci_arttext

  43. Sharma A, Sinha RJ, Singh V, Garg G, Agarwal S, Pandey S. Implications of the Fracture Risk Assessment Algorithm for the assessment and improvement of bone health in patients with prostate cancer: A comprehensive review. Turk J Urol. 2019 [Acceso 12/09/2020];45(4):245-53. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619849/

  44. Cuba. Centro Nacional de Información de Ciencias Médicas. Biblioteca Médica Nacional. VIH/Sida. Estadísticas Mundiales. Factográfico de salud. 2018 Feb [Acceso 12/09/2020];4(2). Disponible en: http://files.sld.cu/bmn/files/2018/02/factografico-de-salud-febrero-2018.pdf

  45. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PloS One. 2013 [Acceso 12/09/2020];8(12):e81355. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867319/

  46. Gullón Ojesto A, García Vadillo JA. Osteoporosis in human immunodeficiency virus-infected patients Seminarios de la Fundación Española de Reumatología. Principio del formulario. 2013 [Acceso 12/09/2020];14(1):18-23. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1577356612000681

  47. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. The Lancet. 2013 [Acceso 12/09/2020];382(9903):1525-33. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0140673613618097

  48. Reyes Llerena GA, Guibert Toledano M, Millán Marcelo C, Pérez Ávila J, Cataneda Yarman DP, Navarro Camero A, et al. New and Old Forms of Rheumatic Manifestations associated with HIV-AIDS Infection: 25 Years after the Beginning of the Epidemic in Cuba. Panamerican Congress of Rheumatology. J Clinical Rheumatology. 2018 [Acceso 12/09/2020];24:S172-3. Disponible en: https://journals.lww.com/jclinrheum/Fulltext/2018/04001/Abstracts,_20th_PANLAR_Meeting__Buenos_Aires,.1.aspx

  49. Premaor MO, Compston JE. The hidden burden of fractures in people living with HIV. JBMR Plus. 2018 [Acceso 12/09/2020];2(5):247-56. Disponible en: https://asbmr.onlinelibrary.wiley.com/doi/abs/10.1002/jbm4.10055

  50. Reyes Llerena GA, Guibert Toledano M, Torres Figueroa A, Navarro Camero A, Torres Carballeira R, Reyes Guibert G, et al. Enfermedades reumáticas y complicaciones metabólicas en pacientes con VIH-SIDA con tratamiento antirretroviral de alta eficiencia. Rev Cubana Reumatol. 2018 [Acceso 12/09/2020];20(3):e650. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962018000300005&lng=es

  51. Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G. Five years of anti-resorptive activity after a single dose of zoledronate results from a randomized double-blind placebo-controlled trial. Bone. 2012 [Acceso 12/09/2020];50(6):1389-93. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S875632821200734X

  52. Mondy K, Powderly WG, Claxton SA, Yarasheski KH, Royal M, Stoneman JS. Alendronate, vitamin D and calcium for the treatment of osteopenia/osteoporosis associated to HIV infection. J Adquir Immune Defic Syndr. 2005 [Acceso 12/09/2020];38(4):426-31. Disponible en: https://journals.lww.com/jaids/fulltext/2005/04010/Alendronate,_Vitamin_D,_and_Calcium_for_the.7.aspx?casa_token=w3fbxSh

  53. Dong HV, Cortes YI, Shiau S, Yin MT. Osteoporosis and fractures in HIV/hepatitis C virus coinfection: a systematic review and meta-analysis. AIDS. 2014 [Acceso 12/09/2020];28(14):2119-31. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940983/

  54. Mahungu TW, Rodger AJ, Johnson MA. HIV as a chronic disease. Clinical Medicine. 2009;9(2):125.

  55. Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A, McCloskey EV, et al. A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016 [Acceso 12/09/2020];11(1):25. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27465509/

  56. Brown TT, Hoy J, Borderi M, Guaraldi G, Renjifo B, Vescini F, et al. Recommendations for Evaluation and Management of Bone Disease in HIV. Clinical Infectious Diseases. 2015 [Acceso 12/09/2020];60(8):1242-51. Disponible en: https://academic.oup.com/cid/article/60/8/1242/2462854?login=true

  57. Yin MT, Falutz J. How to predict risk of fracture in HIV? Curr Opin HIVAIDS. 2016 [Acceso 10/10/2020];11(3):261-7. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399770/

  58. Amiel C, Ostertag A, Siama L, Baudoin C, N’Guyen T, Lajeunie E, et al. BMD is reduced in HIV infected men irrespective of treatment. J Bone Miner Res. 2004 [Acceso 10/10/2020];19(3):402-9. Disponible en: https://asbmr.onlinelibrary.wiley.com/doi/abs/10.1359/JBMR.0301246

  59. Biver E, Calmy A, Aubry-Rozier B, Birkhäuser M, Bischoff-Ferrari HA, Ferrari S, et al. Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis. Osteoporos Int. 2019 [Acceso 10/10/2020];30(5):1125-35. Disponible en: https://link.springer.com/article/10.1007/s00198-018-4794-0




2020     |     www.medigraphic.com